Human-derived anti-huntingtin (HTT) antibodies and uses thereof
US11401325B2 · kind B2 · utility
0Cited by
11References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 7, 2020 |
| Grant date | Aug 2, 2022 |
| Priority date | — |
| Expiry date | Feb 7, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2835
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are novel human-derived anti-huntingtin (HTT) antibodies and biotechnological derivatives thereof, preferably capable of binding mutated and/or aggregated HTT species and or fragments thereof, as well as methods related thereto. The human-derived anti-HTT antibodies and biotechnological derivatives can be used in pharmaceutical and diagnostic compositions for HTT targeted immunotherapy of Huntington Disease and diagnosis thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.